MannKind Corporation

NASDAQ:MNKD

Biotechnology

Healthcare
$4.07 -0.51%

-$0.02 today

Market cap
$1.31B
Beta
1.11
P/E (TTM)
-50.3
EPS (TTM)
-$0.08
52W Low $2.23High $6.51

Volume 2.12M

Average 5.73M

MNKD Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

MannKind CorporationNASDAQ: MNKD

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense declines year over year

Q1 FY2026 income tax expense of $253K fell 44.9% year over year, ahead of the -249.2% change in trailing-twelve-month income tax expense.

Context

  • Income tax expense amounted to 1.3% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -44.9% holds above the trailing-twelve-month pace of -249.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$253K+105.1% QoQ
Last fiscal yearDec 2025
-$4.46M-252.1% YoY
LTMMar 2026
-$4.66M-249.2% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.9%——
1 year-252.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(4.46M) USD
Year-over-year change
-252.1%

Income Tax Expense vs competitors

How MNKD compares with its peers on the latest reported figures

  • MNKD's LTM Mar 2026 income tax expense of -$4.66M is the lowest of the 6 companies compared; the peer median is $0.
  • Its year-over-year change of -249.2% is the lowest of 5, against a peer median of +112.1%.
  • Income tax expense amounts to 1.3% of revenue for MNKD, versus a peer median of 0.0%.
MNKD Competitors Peer median
Income Tax Expense for MNKD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TBPHTheravance Biopharma, Inc.LTM Mar 2026$22.37M +124.1%+1274.1%20.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$21.85M +480.1%+383.6%—
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$0 +100.0%—0.0%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$0 ——0.0%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026-$80K -127.8%—0.1%
MNKDMannKind CorporationLTM Mar 2026-$4.66M -249.2%—1.3%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding MNKD) $0+112.1%+828.9%0.0%

Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.44M99.77M198.96M285.5M348.97M
Cost of Revenue38.86M57.5M62.77M76.6M61.16M
Gross Profit36.59M42.27M136.19M208.9M287.81M
Gross Margin48.5%42.4%68.5%73.2%82.5%
Research & Development12.31M19.72M31.28M45.89M66.35M
Selling, General & Admin77.42M91.47M94.31M94.33M144.14M
Operating Expenses83.61M106.38M127.51M136.32M249.01M
Depreciation & Amortization3.24M6.31M4.54M8.97M12.28M
EBITDA(61.11M)(56.32M)15.13M77.47M27.52M
EBITDA Margin-81.0%-56.4%7.6%27.1%7.9%
Operating Income(47.02M)(64.11M)8.68M72.59M38.8M
Operating Margin-62.3%-64.3%4.4%25.4%11.1%
Interest Income112K2.51M6.15M12.62M0
Interest Expense16.58M24.77M25.16M37.98M13.83M
Other Income / Expenses(33.9M)(23.29M)(19.06M)(42.07M)(37.39M)
Income Before Tax(80.93M)(87.4M)(10.38M)30.52M1.41M
Pre-Tax Margin-107.3%-87.6%-5.2%10.7%0.4%
Income Tax Expense001.56M2.93M(4.46M)
Net Income(80.93M)(87.4M)(11.94M)27.59M5.86M
Net Margin-107.3%-87.6%-6.0%9.7%1.7%
EPS (Basic)(0.37)(0.44)(0.04)0.100.02
EPS (Diluted)(0.37)(0.44)(0.04)0.100.02
Weighted Avg Shares249.24M257.09M267.01M274.42M305.64M
Weighted Avg Shares (Diluted)249.24M257.09M267.01M283.84M314.11M

MannKind Corporation

NASDAQ:MNKD

Intrinsic Alpha fair value

Locked

Current Price

$4.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.